Cardinal Health (CAH) recently reported an 11% year-over-year revenue increase and raised its fiscal 2026 non-GAAP EPS guidance, a combination that has coincided with stronger demand for high-margin specialty drugs and renewed attention on the stock.

The recent guidance hike and specialty drug momentum have come alongside strong price action in Cardinal Health stock, with a 30 day share price return of 16.66% and a 1 year total shareholder return of 39.64%, which suggests that momentum has been building rather than fading.

If this kind of move has you thinking about what else is gaining traction in healthcare, it could be worth scanning other opportunities in AI driven healthcare using the 41 healthcare AI stocks.

With Cardinal Health stock rising over the past year, analyst targets suggesting some upside, and one estimate of intrinsic value indicating a steeper discount, should you view this as a potentially undervalued opportunity, or assume the market is already pricing in future growth?

Most Popular Narrative: 7.2% Undervalued

At a last close of $227.72 versus a narrative fair value of $245.27, the most followed view sees Cardinal Health trading at a discount that hinges on specific growth and margin assumptions.

The analysts have a consensus price target of $245.27 for Cardinal Health based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $215.0.

Want to see what underpins that gap between price and fair value? The narrative leans on steady revenue gains, modest margin improvement and a premium earnings multiple that is anything but generic.

Result: Fair Value of $245.27 (UNDERVALUED)

However, for Cardinal Health the picture is not one way. Tighter regulation and pricing scrutiny, or the loss of major customer contracts, are both capable of challenging that upside story.

Another View: Cardinal Health Stock Through a P/E Lens

While the narrative fair value suggests Cardinal Health stock is 7.2% undervalued, the current P/E of 34.3x tells a different story. It sits above the US Healthcare industry at 23.2x, above peers at 25.9x, and above a fair ratio of 26.9x. This points to valuation risk if sentiment cools.

If the market shifts closer to that fair ratio, the adjustment would happen through price rather than earnings. It is therefore worth asking how comfortable you are paying a premium multiple for Cardinal Health today, and what might make that premium feel justified a few years from now.

Next Steps

Given the mix of optimism and caution around Cardinal Health, it makes sense to look at the underlying data yourself and decide where you stand. To weigh both sides of the story quickly and clearly, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Cardinal Health?

If Cardinal Health has sharpened your focus, do not stop here. Widening your search can surface opportunities that fit your goals even better.

• Spot potential bargains early by scanning companies that pass quality checks in the screener containing 20 high quality undiscovered gems.
• Strengthen your core holdings by reviewing companies highlighted in the solid balance sheet and fundamentals stocks screener (48 results).
• Build a cash flow focused watchlist by assessing payout opportunities through the 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.